Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy

Cancer development is driven by activated oncogenes and loss of tumor suppressors. While oncogene inhibitors have entered routine clinical practice, tumor suppressor reactivation therapy remains to be established. For the most frequently inactivated tumor suppressor p53, genetic mouse models have de...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimovich, Boris, Mutlu, Samet, Schneikert, Jean, Elmshäuser, Sabrina, Klimovich, Maria, Nist, Andrea, Mernberger, Marco, Timofeev, Oleg, Stiewe, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2019
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825290/
https://www.ncbi.nlm.nih.gov/pubmed/31611375
http://dx.doi.org/10.1073/pnas.1910255116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825290/
https://www.ncbi.nlm.nih.gov/pubmed/31611375
http://dx.doi.org/10.1073/pnas.1910255116

Ejemplares similares